With Akebia Therapeutics, Inc. (NASDAQ:AKBA) price’s latest movement, it is now -37.84% away from its 1-year high and 38.65% higher than its 1-year low price. In the past seven days, the stock price volatility for Akebia Therapeutics, Inc. was 6.15%, whereas its volatility in the past 30 days has been 6.35%. This public company’s stock also has a beta score of 1.46. When the beta value is less/more than 1, it can imply that the stock is less/more volatile than the wider stock market – a metric that traders will surely be keeping tabs on.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) most recently published its quarterly earnings results. The firm posted -$0.23 earnings per share (EPS) for the three-month period, surpassing analysts’ consensus estimate of -$0.24 by $0.01. The publicly-traded organization reported revenue of $59.85 million for the quarter, compared to the average analyst forecast calling for $73.67 million, which was missing the analyst consensus estimate.
Shares of Akebia Therapeutics, Inc. (AKBA) plunged -4.76%, amounting to a loss of -$0.36 per share, to finish the regular trading session at $7.21 on Friday April 12th, 2019. After beginning the session at $7.60, shares of Akebia Therapeutics, Inc. reached as high as $7.71 during the day, while hitting a 1-day low of $7.13. Trade volume reached 1,495,965 shares against this stock’s average daily volume of 1.16M shares, with a total float of 107.49M. As a consequence of the price decrease, Akebia Therapeutics, Inc. now has a current market value of 825.47M.
MiMedx Group, Inc. (NASDAQ:MDXG) subtracted -8.63% to its trading price by the close of the most recent session, dropping from its previous closing price of $3.65 to $3.34. This stock increased in value by -15.57% during the last 7-day period, and experienced a loss of 7.58% over the past 30-day period. In the past three months, this stock’s price grew by 38.38% , and subtracted -38.69% to its price during the last six months of trading. MDXG demonstrated a yearly price loss of -52.01% , while its year-to-date (YTD) price performance has been up 86.31% . This stock’s price changed by +38.38% compared to its 90-day low, and moved down -19.83% comparing to its 90-day high price.
Have a quick look on short, medium and long-term indicators. According to the Composite Indicator, Trendspotter rated the MDXG stock as “Sell”. In the short-term, MiMedx Group, Inc. (MDXG) has a 20-day average volume of 508,515 shares and short-term indicators sets the MDXG stock as “ 40% Sell ” on average basis. In the medium-term, MDXG stock has a 50-Day average volume of 693,910 shares and medium-term indicators gave the average rating of “ 25% Buy ”, while in the long-term period the stock has a 100-Day average volume of 1,591,372 shares. On average, long-term indicators rated the stock as “67% Buy ”. The overall picture from all short, medium and long-term indicators sets the MDXG stock as “Hold Overall Average Signal calculated from all 13 indicators. Signal Strength is a long-term measurement of the historical strength of the Signal, while Signal Direction is a short-term (3-Day) measurement of the movement of the Signal.” on average basis.
Recently, multiple brokerages have sent out reports on MDXG. Lake Street, for example, Downgrade its rating on shares of MiMedx Group, Inc. from “Buy ” to a “ Hold”according to a research note from Monday February 26th, 2018. while giving the stock a “ Hold” from “Strong Buy ” rating, as stated in a research report from Tuesday, February 20th, 2018. Needham, on the other hand, Downgrade a from “Buy ” to “ Hold” rating on this stock in a research note dated Tuesday, February 20th, 2018.
In other news related to MiMedx Group, Inc. stock, 20.83% shares of MDXG held by institutions. The total number of institutions who held the MDXG shares was 45, according to most recent SEC filling. During the past quarter, total 23,130,358 shares held by institutions with the net change of -575,204 shares. In the meantime, 1 new institutions bought the shares of MiMedx Group, Inc. for the first time and 3 institutions sold all their holdings in the company’s common stock. 1 institutions increased their investment in the MDXG stock and 4 institutions decreased their investment in the MiMedx Group, Inc. (MDXG)’s stock during the last quarter.